Literature DB >> 22418724

Mouse models for Chikungunya virus: deciphering immune mechanisms responsible for disease and pathology.

Teck-Hui Teo1, Fok-Moon Lum, Wendy W L Lee, Lisa F P Ng.   

Abstract

Chikungunya virus (CHIKV), an alphavirus, has been responsible for large epidemic outbreaks with serious economic and social impact during the last 6 years. Transmitted by Aedes mosquitoes, it causes Chikungunya fever, an acute illness in patients with a stooped posture often associated with chronic and incapacitating arthralgia. The unprecedented re-emergence has stimulated renewed interest in CHIKV. This review discusses the advantages and disadvantages of different animal models for CHIKV infections and their importance to study the role of the immune system in different pathologies caused by CHIKV. We also reveal how such studies still present a difficult challenge, but are indispensible for mechanistic studies to further understand the pathophysiology of CHIKV infections.

Entities:  

Mesh:

Year:  2012        PMID: 22418724     DOI: 10.1007/s12026-012-8266-x

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  117 in total

1.  Role of γδ T cells in antibody production and recovery from SFV demyelinating disease.

Authors:  Farinaz Safavi; Jason P Feliberti; Cedric S Raine; Foroozan Mokhtarian
Journal:  J Neuroimmunol       Date:  2011-05-25       Impact factor: 3.478

2.  Cell interactions in the induction of tolerance: the role of thymic lymphocytes.

Authors:  R K Gershon; K Kondo
Journal:  Immunology       Date:  1970-05       Impact factor: 7.397

3.  Chikungunya virus nonstructural protein 2 inhibits type I/II interferon-stimulated JAK-STAT signaling.

Authors:  Jelke J Fros; Wen Jun Liu; Natalie A Prow; Corinne Geertsema; Maarten Ligtenberg; Dana L Vanlandingham; Esther Schnettler; Just M Vlak; Andreas Suhrbier; Alexander A Khromykh; Gorben P Pijlman
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

4.  A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.

Authors:  Karthik Mallilankaraman; Devon J Shedlock; Huihui Bao; Omkar U Kawalekar; Paolo Fagone; Aarthi A Ramanathan; Bernadette Ferraro; Jennifer Stabenow; Paluru Vijayachari; Senthil G Sundaram; Nagarajan Muruganandam; Gopalsamy Sarangan; Padma Srikanth; Amir S Khan; Mark G Lewis; J Joseph Kim; Niranjan Y Sardesai; Karuppiah Muthumani; David B Weiner
Journal:  PLoS Negl Trop Dis       Date:  2011-01-11

5.  Virulence variation among isolates of western equine encephalitis virus in an outbred mouse model.

Authors:  Christopher H Logue; Christopher F Bosio; Thomas Welte; Kimberley M Keene; Jeremy P Ledermann; Aaron Phillips; Brian J Sheahan; Dennis J Pierro; Nicole Marlenee; Aaron C Brault; Catharine M Bosio; Amber J Singh; Ann M Powers; Ken E Olson
Journal:  J Gen Virol       Date:  2009-04-29       Impact factor: 3.891

6.  The type I interferon system protects mice from Semliki Forest virus by preventing widespread virus dissemination in extraneural tissues, but does not mediate the restricted replication of avirulent virus in central nervous system neurons.

Authors:  Rennos Fragkoudis; Lucy Breakwell; Clive McKimmie; Amanda Boyd; Gerald Barry; Alain Kohl; Andres Merits; John K Fazakerley
Journal:  J Gen Virol       Date:  2007-12       Impact factor: 3.891

Review 7.  Chikungunya: an overview.

Authors:  A B Sudeep; D Parashar
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

8.  An animal model for studying the pathogenesis of chikungunya virus infection.

Authors:  Sarah A Ziegler; Liang Lu; Amelia P A Travassos da Rosa; Shu-Yuan Xiao; Robert B Tesh
Journal:  Am J Trop Med Hyg       Date:  2008-07       Impact factor: 2.345

9.  Indirect mouse model for the evaluation of potential antiviral compounds: results with Venezuelan equine encephalomyelitis virus.

Authors:  R W Kuehne; W L Pannier; E L Stephen
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

10.  Human muscle satellite cells as targets of Chikungunya virus infection.

Authors:  Simona Ozden; Michel Huerre; Jean-Pierre Riviere; Lark L Coffey; Philippe V Afonso; Vincent Mouly; Jean de Monredon; Jean-Christophe Roger; Mohamed El Amrani; Jean-Luc Yvin; Marie-Christine Jaffar; Marie-Pascale Frenkiel; Marion Sourisseau; Olivier Schwartz; Gillian Butler-Browne; Philippe Desprès; Antoine Gessain; Pierre-Emmanuel Ceccaldi
Journal:  PLoS One       Date:  2007-06-13       Impact factor: 3.240

View more
  23 in total

1.  A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

Authors:  Juan García-Arriaza; Victoria Cepeda; David Hallengärd; Carlos Óscar S Sorzano; Beate Mareike Kümmerer; Peter Liljeström; Mariano Esteban
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

Review 2.  Mosquito Saliva Reshapes Alphavirus Infection and Immunopathogenesis.

Authors:  Siew-Wai Fong; R Manjunatha Kini; Lisa F P Ng
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

Review 3.  Vaccine and Therapeutic Options To Control Chikungunya Virus.

Authors:  Ann M Powers
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

Review 4.  Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.

Authors:  Laurie A Silva; Terence S Dermody
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

Review 5.  Chikungunya Infection: a Global Public Health Menace.

Authors:  A J Mathew; A Ganapati; J Kabeerdoss; A Nair; N Gupta; P Chebbi; S K Mandal; Debashish Danda
Journal:  Curr Allergy Asthma Rep       Date:  2017-02       Impact factor: 4.806

6.  An essential role of antibodies in the control of Chikungunya virus infection.

Authors:  Fok-Moon Lum; Teck-Hui Teo; Wendy W L Lee; Yiu-Wing Kam; Laurent Rénia; Lisa F P Ng
Journal:  J Immunol       Date:  2013-05-13       Impact factor: 5.422

7.  A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.

Authors:  Shirley Lam; Min Nyo; Patchara Phuektes; Chow Wenn Yew; Yee Joo Tan; Justin Jang Hann Chu
Journal:  MAbs       Date:  2015-08-25       Impact factor: 5.857

8.  Viremia in North American Mammals and Birds After Experimental Infection with Chikungunya Viruses.

Authors:  Angela M Bosco-Lauth; Nicole M Nemeth; Dennis J Kohler; Richard A Bowen
Journal:  Am J Trop Med Hyg       Date:  2015-12-14       Impact factor: 2.345

9.  Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.

Authors:  David Hallengärd; Maria Kakoulidou; Aleksei Lulla; Beate M Kümmerer; Daniel X Johansson; Margit Mutso; Valeria Lulla; John K Fazakerley; Pierre Roques; Roger Le Grand; Andres Merits; Peter Liljeström
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

Review 10.  Chikungunya Virus Vaccines: Platforms, Progress, and Challenges.

Authors:  Victor R DeFilippis
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.